APFID

Home > Latest News on ID > Interesting Papers

LOGIN
Treatment options for nosocomial pneumonia due to MRSA
J Infect. 2009 Sep;59 Suppl 1:S25-31
Date: 2009-10-01   Read: 156017

J Infect. 2009 Sep;59 Suppl 1:S25-31

Treatment options for nosocomial pneumonia due to MRSA

Niederman MS

Nosocomial pneumonia, which includes hospital-acquired pneumonia, ventilator-associated pneumonia, and health care associated pneumonia, remains an important cause of morbidity and mortality. The continuing emergence of methicillin-resistant Staphylococcus aureus (MRSA) as a nosocomial pneumonia pathogen is particularly problematic not only because of its prevalence, but also because antimicrobial resistance is increasingly associated with inappropriate empirical antibiotic therapy. As a result, intensivists are faced with the dual goals of providing initial accurate broad-spectrum antibiotic coverage to reduce mortality while minimizing the risk for the emergence of antimicrobial resistance. These competing goals can be achieved by using an approach that initially delivers liberal broad-spectrum coverage followed by de-escalation once culture results and serial clinical observations become available. In ventilator-associated pneumonia, linezolid has demonstrated favorable activity against Gram-positive bacteria, including MRSA, and is recommended in evidence-based guidelines as an alternative to vancomycin, particularly when MRSA is documented as the etiology.



Next Incidence of and risk factors for nosocomial bloodstream infections in adults in the United States, 2003
Infect Control Hosp Epidemiol. 2009;30(11):1036-44
2009-10-14 155165
Previous Multidrug-resistant Gram-negative infections: what are the treatment options?
Drugs. 2009;69(14):1879-901.
2009-10-01 155674
޴ٷΰ ΰ